Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Organigram Global Inc. (OGI)

    Price:

    1.60 USD

    ( + 0.03 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    OGI
    Name
    Organigram Global Inc.
    Industry
    Drug Manufacturers - Specialty & Generic
    Sector
    Healthcare
    Price
    1.600
    Market Cap
    214.214M
    Enterprise value
    131.002M
    Currency
    USD
    Ceo
    Beena G. Goldenberg
    Full Time Employees
    1093
    Ipo Date
    2019-05-21
    City
    Moncton
    Address
    35 English Drive

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Viatris Inc.

    VALUE SCORE:

    6

    Symbol
    VTRS
    Market Cap
    12.417B
    Industry
    Drug Manufacturers - Specialty & Generic
    Sector
    Healthcare

    2nd position

    Amphastar Pharmaceuticals, Inc.

    VALUE SCORE:

    10

    Symbol
    AMPH
    Market Cap
    1.418B
    Industry
    Drug Manufacturers - Specialty & Generic
    Sector
    Healthcare

    The best

    Lantheus Holdings, Inc.

    VALUE SCORE:

    11

    Symbol
    LNTH
    Market Cap
    3.958B
    Industry
    Drug Manufacturers - Specialty & Generic
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    37.907
    P/S
    1.316
    P/B
    0.764
    Debt/Equity
    0.024
    EV/FCF
    -15.800
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    1.197
    Earnings yield
    0.026
    Debt/assets
    0.016
    FUNDAMENTALS
    Net debt/ebidta
    -7.034
    Interest coverage
    0
    Research And Developement To Revenue
    0.042
    Intangile to total assets
    0.183
    Capex to operating cash flow
    7.155
    Capex to revenue
    0.088
    Capex to depreciation
    1.225
    Return on tangible assets
    0.017
    Debt to market cap
    0.031
    Piotroski Score
    5.000
    FUNDAMENTALS
    PEG
    -0.398
    P/CF
    107.568
    P/FCF
    -17.473
    RoA %
    1.377
    RoIC %
    15.907
    Gross Profit Margin %
    33.774
    Quick Ratio
    1.422
    Current Ratio
    2.589
    Net Profit Margin %
    3.472
    Net-Net
    -0.273
    FUNDAMENTALS PER SHARE
    FCF per share
    -0.127
    Revenue per share
    1.671
    Net income per share
    0.058
    Operating cash flow per share
    0.021
    Free cash flow per share
    -0.127
    Cash per share
    0.275
    Book value per share
    2.879
    Tangible book value per share
    2.109
    Shareholders equity per share
    2.879
    Interest debt per share
    0.068
    TECHNICAL
    52 weeks high
    2.045
    52 weeks low
    0.850
    Current trading session High
    1.630
    Current trading session Low
    1.550
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    CA
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    237.967
    logo

    Country
    CA
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.647
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    -0.437838%
    P/E
    -9.587
    logo

    Country
    CA
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    56.171
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -8.370
    logo

    Country
    CA
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -8.201
    logo

    Country
    CA
    Sector
    Consumer Defensive
    Industry
    Agricultural Farm Products
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    32.146
    DESCRIPTION

    Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.

    NEWS
    https://images.financialmodelingprep.com/news/organigram-the-capital-efficient-market-leader-trading-at-a-20250818.jpg
    Organigram: The Capital Efficient Market Leader Trading At A Discount

    seekingalpha.com

    2025-08-18 10:34:27

    Organigram Global Inc. presents a unique value proposition through its disciplined approach of doubling down on the Canadian market and cautiously expanding its footprint globally. Margin headwinds witnessed in Q3 can be easily addressed through the increased harvesting capacity following optimizations and upgrades. Canadian LPs redirecting their cannabis to international markets allowed Organigram to become the market leader in terms of market share and widen its gap with its nearest competitor, Tilray.

    https://images.financialmodelingprep.com/news/organigram-global-inc-ogi-q3-2025-earnings-call-transcript-20250813.jpg
    Organigram Global Inc. (OGI) Q3 2025 Earnings Call Transcript

    seekingalpha.com

    2025-08-13 15:03:44

    Title: Organigram Global Inc. (NASDAQ:OGI ) Q3 2025 Earnings Call August 13, 2025 8:00 AM ET Company Participants Beena G. Goldenberg - CEO & Director Greg Guyatt - Chief Financial Officer Max Schwartz - Director of Investor Relations Conference Call Participants Aaron Thomas Grey - Alliance Global Partners, Research Division Frederico Yokota Choucair Gomes - ATB Capital Markets Inc., Research Division Operator Good morning.

    https://images.financialmodelingprep.com/news/organigram-posts-wider-loss-eyes-profitability-in-near-term-20250813.jpg
    Organigram Posts Wider Loss, Eyes Profitability In Near Term

    benzinga.com

    2025-08-13 10:38:59

    Cannabis grower Organigram Holdings Inc. OGI reported third-quarter 2025 net sales of $51.14 million, approximately $70.8 million Canadian dollars (CAD), up 72% year-over-year, beating the consensus of $48.33 million.

    https://images.financialmodelingprep.com/news/organigram-ogi-reports-q3-loss-beats-revenue-estimates-20250813.jpg
    OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

    zacks.com

    2025-08-13 09:51:31

    OrganiGram (OGI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.02 per share a year ago.

    https://images.financialmodelingprep.com/news/organigram-reports-record-third-quarter-fiscal-2025-results-20250813.jpg
    Organigram Reports Record Third Quarter Fiscal 2025 Results

    businesswire.com

    2025-08-13 06:00:00

    TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, is pleased to announce its record results for the third quarter ended June 30, 2025 (“Q3 Fiscal 2025” or “Q3”). Q3 FISCAL 2025 HIGHLIGHTS Record Gross Revenue: $110.2 million (+73% year-over-year, +7.2% sequential). Record Net Revenue: $70.8 million (+72% year-over-year, +7.9% sequential). International Revenue: $7.4 million (+208% year-over-.

    https://images.financialmodelingprep.com/news/organigram-to-report-third-quarter-fiscal-2025-results-on-20250801.jpg
    Organigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025

    businesswire.com

    2025-08-01 06:00:00

    TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today it will report earnings results for its third quarter fiscal 2025 ended June 30, 2025, on Wednesday, August 13, 2025, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, August 13, 2025 Time: 8:00 am Eastern Time To register for the conference call, plea.

    https://images.financialmodelingprep.com/news/organigram-global-scales-us-presence-with-collective-project-directtoconsumer-20250708.jpg
    Organigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage Portfolio

    businesswire.com

    2025-07-08 06:00:00

    TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today that its recently acquired beverage business, Collective Project, has launched an e-commerce platform in the U.S. marking a key milestone in the Company's strategic expansion into the rapidly evolving U.S. hemp-derived THC beverage market. The launch also includes a bold new portfolio of hemp-derived THC beverages designed to m.

    https://images.financialmodelingprep.com/news/americans-should-buy-canadian-cannabis-companies-20250705.jpg
    Americans Should Buy Canadian Cannabis Companies

    seekingalpha.com

    2025-07-05 07:30:11

    Canadian LPs offer compelling risk/reward versus U.S. cannabis stocks, with stronger balance sheets, tangible book value, and global opportunities due to federal legality. Despite recent rallies, Canadian LPs remain cheap on enterprise value to EBITDA, especially Village Farms, Organigram, and Tilray Brands, which I hold in my model portfolio. U.S. MSOs face significant risks from 280E tax liabilities and negative tangible equity, making Canadian LPs a safer bet for cannabis investors right now.

    https://images.financialmodelingprep.com/news/june-2025-watchlist-best-canadian-cannabis-stocks-for-growth-20250531.jpg
    June 2025 Watchlist: Best Canadian Cannabis Stocks for Growth

    marijuanastocks.com

    2025-05-31 10:00:52

    As of June 2025, the U.S. cannabis industry continues its rapid expansion. Projections estimate the market will reach approximately $45 billion in revenue this year. This growth is fueled by increasing consumer demand, introducing innovative products, and technological advancements in cultivation and production. Despite federal prohibition, 24 states have legalized adult-use cannabis, and 39 states have legalized medical cannabis. However, federal legalization efforts face challenges. In May 2025, the 1st U.S. Circuit Court of Appeals upheld the federal ban on marijuana, rejecting a legal challenge by several Massachusetts cannabis businesses. This decision underscores the ongoing tension between federal law and evolving state cannabis regulations. Additionally, while the Biden administration has proposed reclassifying marijuana to a less restricted category, the outcome remains uncertain, especially under a new administration.

    https://images.financialmodelingprep.com/news/organigram-global-announces-ceo-succession-plan-20250527.jpg
    Organigram Global Announces CEO Succession Plan

    businesswire.com

    2025-05-27 06:00:00

    TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (“the Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today that Ms. Beena Goldenberg, CEO, Organigram, will be retiring at the conclusion of the Company's current fiscal year ending September 30, 2025. Until this date, Ms. Goldenberg will continue in her role as CEO and as a member of the Company's Board of Directors (the “Board”) to advance Organigram's strategic objectives, including.

    https://images.financialmodelingprep.com/news/organigram-global-reports-record-q2-2025-revenues-as-global-20250516.jpg
    Organigram Global Reports Record Q2 2025 Revenues As Global Footprint Expands

    seekingalpha.com

    2025-05-16 14:39:22

    Organigram Global reported record-high revenues for Q2 and improved net income. The company is now selling cannabis beverages in Canada and hemp-derived cannabis beverages in the US. Organigram Global is ramping up its facilities in Canada to meet international demand.

    https://images.financialmodelingprep.com/news/organigram-ogi-reports-q2-loss-beats-revenue-estimates-revised-20250512.jpg
    OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)

    zacks.com

    2025-05-12 20:15:33

    OrganiGram (OGI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.12 per share a year ago.

    https://images.financialmodelingprep.com/news/organigram-lights-up-q2-with-74-sales-surge-profitable-turn-20250512.jpg
    Organigram Lights Up Q2 With 74% Sales Surge, Profitable Turn

    benzinga.com

    2025-05-12 10:40:53

    Cannabis grower Organigram Holdings Inc  OGI reported second-quarter 2025 net sales of $45.7 million (approximately CA$65.6 million). That's up 74% year-over-year, beating the consensus of $42.28 million.

    https://images.financialmodelingprep.com/news/organigram-global-inc-ogi-q2-2025-earnings-call-transcript-20250512.jpg
    Organigram Global Inc. (OGI) Q2 2025 Earnings Call Transcript

    seekingalpha.com

    2025-05-12 10:16:35

    Organigram Global Inc. (NASDAQ:OGI ) Q2 2025 Earnings Conference Call May 12, 2025 8:00 AM ET Company Participants Max Schwartz - Investor Relations Beena Goldenberg - Chief Executive Officer Greg Guyatt - Chief Financial Officer Conference Call Participants Aaron Grey - Alliance Global Partners Frederico Gomes - ATB Capital Markets Yewon Kang - Canaccord Genuity Operator Good morning. My name is Krista, and I will be your conference operator today.

    https://images.financialmodelingprep.com/news/organigram-ogi-reports-q2-loss-misses-revenue-estimates-20250512.jpg
    OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates

    zacks.com

    2025-05-12 08:45:36

    OrganiGram (OGI) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.12 per share a year ago.

    https://images.financialmodelingprep.com/news/organigram-reports-record-second-quarter-fiscal-2025-results-20250512.jpg
    Organigram Reports Record Second Quarter Fiscal 2025 Results

    businesswire.com

    2025-05-12 06:00:00

    TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 (“Q2 Fiscal 2025”). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company's acquisition of Motif Labs Ltd. ("Motif") on December 6, 2024. Q2 FISCAL 2025 HIGHLIGHTS Gross revenue increased 79% to $102.8 million from $57.4 million in.